Adjuvant bisphosphonates in breast cancer: Are we witnessing the emergence of a new therapeutic strategy?

European Journal of Cancer

Volumn 45, Issue 11, 2009, Pages 1909-1915

  Coleman, R E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Breast; Therapeutics

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DENOSUMAB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GOSERELIN; HYDROXYAPATITE; IBANDRONIC ACID; LETROZOLE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; SOMATOMEDIN C; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANDROGEN DEPRIVATION THERAPY; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE DENSITY; BONE DESTRUCTION; BONE METASTASIS; BONE MINERAL; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CELL SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG TARGETING; FRAGILITY FRACTURE; HIGH RISK PATIENT; HUMAN; JAW OSTEONECROSIS; LUNG NON SMALL CELL CANCER; MICROMETASTASIS; MULTIPLE MYELOMA; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OVERALL SURVIVAL; PATHOPHYSIOLOGY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN SECRETION;

BONE NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLODRONIC ACID; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67649363481     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.04.022     Document Type: Article

References (35)

1. Shibuya K., Mathers C.D., Boschi-Pinto C., et al. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease. BMC Cancer 2 (2002) 37
2. Albain K.S., de la Garza-Salazar J., Pienkowski T., et al. Reducing the global breast cancer burden: the importance of patterns of care research. Clin Breast Cancer 6 5 (2005) 412-420
3. Coleman R.E. Bisphosphonates: clinical experience. Oncologist 9 Suppl. 4 (2004) 14-27
4. Ralston S.H., and de Crombrugghe B. Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev 20 (2006) 2492-2506
5. Yin J.J., Pollock C.B., and Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res 15 1 (2005) 57-62
6. Yoneda T., and Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328 (2005) 679-687
7. Roodman G.D. Mechanisms of bone metastasis. New Eng J Med 350 (2004) 1655-1664
8. Russell R.G., and Rogers M.J. Bisphosphonates: from the laboratory to the clinic and back again. Bone 25 (1999) 97-106
9. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296 (2001) 235-242
10. Monkkonen H., Auriola S., Lehenkari P., et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Brit J Pharmacol 147 (2006) 437-445
11. Winter M.C., Holen I., and Coleman R.E. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34 5 (2008) 453-475
12. Woodward J., Coleman R.E., and Holen I. Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion. Anticancer Drugs 16 (2005) 11-19
13. Santini D., Vincenzi B., Avvisati G., Dicuonzo G., Battistoni F., Gavasci M., et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8 (2002) 1080-1084
14. Wood J., Bonjean K., Ruetz S., Bellahcene A., Devy L., and Foidart J.M. Novel anti-angiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302 (2002) 1055-1061
15. Jagdev S.P., Coleman R.E., Shipman C.M., Rostami H.A., and Croucher P.I. The bisphosphonate, zoledronic acid. Induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Brit J Cancer 84 (2001) 1126-1134
16. Neville-Webbe H.L., Rostami-Hodjegan A., Evans C.A., Coleman R.E., and Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113 (2005) 364-371
17. Ottewell P.D., Mönkkönen H., Jones M., Lefley D.V., Coleman R.E., and Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100 16 (2008) 1167-1178
18. Mundy G.R., Yoneda T., and Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol 28 (2001) 35-44
19. Powles T.J., Paterson A.E., McCloskey E., et al. Reduction in bone relapse, improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res Treat 8 (2006) R13 [E-publication ahead of print]
20. Diel I.J., Solomayer E.F., Costa S.D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339 (1998) 357-363
21. Diel I.J., Jaschke A., Solomayer E.F., et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 12 (2008) 2007-2011
22. Saarto T., Vehmanen L., Virkkunen P., and Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43 (2004) 650-656
23. Kanis J.A., Powles T., Paterson A.H., McCloskey E.V., and Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19 (1996) 663-667
24. van Holten-Verzantvoort A.T., and Papapoulos S.E. Oral pamidronate in the prevention and treatment of skeletal metastases in patients with breast cancer. Medicina (B Aires) 57 Suppl. 1 (1997) 109-113
25. Kokufu I., Kohno N., Takao S., et al. Adjuvant pamidronate (PMT) therapy for the prevention of bone metastases in breast cancer (BC) patients with four or more positive nodes. ASCO (Ann Meeting Proc) 22 14S (2004) [abstract 530]
26. Jung J, Hwang G, Lee Y, Park H, Yang Y. Pamidronate as adjuvant treatment for prevention of bone metastases in breast cancer. ASCO (Annual Meeting Proceedings) 2005 [Abs 888. 30].
27. Kristensen B., Ejlertsen B., Mouridsen H.T., et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 47 4 (2008) 740-746
28. Rack B., Schindelbeck C., Strobl B., et al. Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study. Dtsch Med Wochenschr 133 7 (2008) 285-289
29. Lin A., Park J., Melisko M., et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow. Cancer Res (2007) 68 [CTRC-AACR San Antonio breast cancer symposium, abstract 510]
30. Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360 7 (2009) 679-691
31. Brufsky A., Bundred N., Coleman R., et al. An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (Bca) receiving adjuvant letrozole (LET). The Breast 16 Suppl. 1 (2007) S57
32. Eidtmann H., Bundred N.J., and DeBoer R. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Cancer Res 69 Suppl. 2 (2008) [CTRC-AACR San Antonio breast cancer symposium, abstract 44]
33. Coleman R., Thorpe H., Cameron D., et al. Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy-first safety data from the AZURE trial (BIG01/04). Breast Cancer Res Treat 100 Suppl. 1 (2006) [abstract 2080]
34. Burkinshaw R., Winter M., Thorpe H., et al. Osteonecrosis of the jaw and dental related adverse events during adjuvant therapy for early breast cancer: initial dental safety findings from the AZURE study. Cancer Treat Rev 34 Suppl. 1 (2008) S75
35. Winter M.C., Thorpe H.C., Burkinshaw R., et al. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response - exploratory evidence for direct anti-tumour activity in breast cancer. Cancer Res 69 Suppl. 2 (2008) [CTRC-AACR San Antonio breast cancer symposium, abstract 5101]